FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease.

Alzheimers Res Ther · 2018 · PMC6201586 · PMID 30355322

Europe PMC DOI

hedged sentence

0.0880

closest p · 1.8× alpha

0.0880

boldest claim

The sentences

did not reach statistical significancep = 0.088so close (0.05 < p ≤ 0.1)

A clearer association between cognitive benefit and IgG AUC was seen for COWAT (Spearman r = 0.673, p = 0.039); the association for ADAS-Cog11 likewise was stronger, but did not reach statistical significance (Spearman r = − 0.576, p = 0.088) (Fig. 6b , d ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.